These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 25544836)

  • 21. A world without Roe: how different would it be?
    Glendon MA
    Hastings Cent Rep; 1989; 19(4):30-1. PubMed ID: 2745061
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patent portfolios after myriad, how to fit in those new genes?
    Aceto JF
    ACS Med Chem Lett; 2013 Aug; 4(8):681-3. PubMed ID: 24900729
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patenting Nucleic Acid Sequences: More Ambiguity from the High Court?
    Lawson C
    J Law Med; 2018 Apr; 25(3):741-764. PubMed ID: 29978665
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Battle brewing over the BRCA1/2 gene patents.
    Agovic A
    Rev Derecho Genoma Hum; 2010; (33):171-94. PubMed ID: 21510137
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The European opposition against the BRCA gene patents.
    Matthijs G
    Fam Cancer; 2006; 5(1):95-102. PubMed ID: 16528613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Strategies for strengthening patent protection of pharmaceutical inventions in light of federal court decisions.
    Pillai X; Kinney WA
    Curr Top Med Chem; 2010; 10(18):1929-36. PubMed ID: 20615184
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Framing Ethical Concerns and Attitudes towards Human Gene Patents in the Chinese Press.
    Du L; Lin S; Kamenova K
    Asian Bioeth Rev; 2020 Sep; 12(3):307-323. PubMed ID: 33717340
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An overview of a recent court challenge to the protection of biomarkers as intellectual property.
    Hall SC; Tromp JM; Jortani SA
    Clin Chim Acta; 2011 May; 412(11-12):802-5. PubMed ID: 21315704
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protecting essential information about genetic variants as trade secrets: a problem for public policy?
    Juergens AK; Francis LP
    J Law Biosci; 2018 Dec; 5(3):682-705. PubMed ID: 31143458
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stem cell patents--reexamination/litigation--the last 5 years.
    Shyntum Y; Kalkreuter E
    Tissue Eng Part B Rev; 2009 Mar; 15(1):87-90. PubMed ID: 19260807
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3.
    Drugs R D; 2005; 6(2):120-7. PubMed ID: 15777106
    [TBL] [Abstract][Full Text] [Related]  

  • 32. AMP v Myriad: the Supreme Court gives a win to personalized medicine.
    Klein RD
    J Mol Diagn; 2013 Nov; 15(6):731-2. PubMed ID: 24139185
    [TBL] [Abstract][Full Text] [Related]  

  • 33. European opposition to exclusive control over predictive breast cancer testing and the inherent implications for U.S. patent law and public policy: a case study of the Myriad Genetics' BRCA patent controversy.
    Paradise J
    Food Drug Law J; 2004; 59(1):133-54. PubMed ID: 15190928
    [No Abstract]   [Full Text] [Related]  

  • 34. Patent protection of diagnostic technology: will recent US Supreme Court decisions change patent strategy?
    Komatani TS
    Pharm Pat Anal; 2015; 4(5):357-62. PubMed ID: 26451906
    [No Abstract]   [Full Text] [Related]  

  • 35. 'The cost will drop'. Myriad Genetics' shares drop as competitors enter.
    Carlson J
    Mod Healthc; 2013 Jun; 43(24):12. PubMed ID: 23875233
    [No Abstract]   [Full Text] [Related]  

  • 36. Mayo, Myriad, America Invents Act and BPCIA: how has the United States biopharmaceutical market been affected?
    Finston SK; Davey NS; Davé E; Ravichandran V; Davey SR; Davé RS
    Pharm Pat Anal; 2016 May; 5(3):159-67. PubMed ID: 27087460
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The patent is political: the consequences of patenting the BRCA genes in Britain.
    Parthasarathy S
    Community Genet; 2005; 8(4):235-42. PubMed ID: 16244478
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of Myriad and Mayo: will advancements in the biological sciences be spurred or disincentivized? (Or was biotech patenting not complicated enough?).
    Gordon J
    Cold Spring Harb Perspect Med; 2014 Dec; 5(5):a020917. PubMed ID: 25502748
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Myriad's impact on gene patents.
    Aboy M; Liddell K; Liddicoat J; Crespo C
    Nat Biotechnol; 2016 Nov; 34(11):1119-1123. PubMed ID: 27824831
    [No Abstract]   [Full Text] [Related]  

  • 40. Teva Pharmaceuticals v. Sandoz: availability of generic glatiramer acetate and the impact to patent litigation claim construction.
    Fogel LE; Ray CJ
    Expert Opin Ther Pat; 2015 Jan; 25(1):1-4. PubMed ID: 25363310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.